Basit öğe kaydını göster

dc.contributor.authorSunbul, Mustafa
dc.contributor.authorLeblebicioglu, Hakan
dc.date.accessioned2020-06-21T15:37:01Z
dc.date.available2020-06-21T15:37:01Z
dc.date.issued2005
dc.identifier.issn1007-9327
dc.identifier.urihttps://hdl.handle.net/20.500.12712/21128
dc.descriptionLeblebicioglu, Hakan/0000-0002-6033-8543en_US
dc.descriptionWOS: 000208102500014en_US
dc.descriptionPubMed: 15800989en_US
dc.description.abstractAIM: Hepatitis B virus (HBV) strains isolated worldwide has been classified into eight genomic groups deduced from genome comparisons and designated as genotypes A to H. We aimed to investigate prevalence of HBV genotypes and subtypes in Turkey. METHODS: A total of 88 chronic hepatitis B (CHB) patients from 15 hospitals throughout the country were included. Patients who were HBsAg positive in serum at least for 6 mo, who had HBV-DNA in serum and elevation of ALT levels more than two times upper limit of normal, and who had percutaneous liver biopsy within 6 mo were included. Genotyping of HBV was done by restriction fragment length polymorphism (RFLP). The patients received subcutaneous 9 MU interferon-alpha 2a thrice a week for a period of 6 mo. RESULTS: Genotype D was detected in 78 of 88 (88.7%) patients, however, genotyping failed in two patients (2.3%), while no product was obtained in eight (9.0%) patients. Regarding subtypes, D2 was more prevalent (67 patients between 78% and 85.9%) followed by subtype D2+deletion (seven patients of 78 or 8.9%), subtype D1 (three patients of 78% or 3.9%) and subtype D3 (one patient of 78% or 1.3%). Thirty-three patients (37.5%) were HBeAg positive compared to 55 (62.5%) anti-HBe positive patients. The endpoint for the viral response of HBeAg positive patients was 27.2%, while it was found 52.7% in HBeAg negative patients (P < 0.05). Long-term persistent viral response was 29.5% for all patients. CONCLUSION: This multi-center study indicates that the predominant genotype with CHB patients in Turkey like in other Mediterranean countries is genotype D. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.en_US
dc.description.sponsorshipROCHE Pharmaceuticals, TurkeyRoche Holdingen_US
dc.description.sponsorshipSupported by a grant from ROCHE Pharmaceuticals, Turkeyen_US
dc.language.isoengen_US
dc.publisherBaishideng Publ Grp Co Ltden_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectGenotypeen_US
dc.subjectInterferon-alpha 2aen_US
dc.titleDistribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkeyen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume11en_US
dc.identifier.issue13en_US
dc.identifier.startpage1976en_US
dc.identifier.endpage1980en_US
dc.relation.journalWorld Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster